ERBB2 and neoplasm: Lastly, HER2-enriched tumours generally display a glycolytic phenotype in line with upregulated PKB/AKT-mammalian Target of Rapamycin Complex 1 (mTORC1) signalling [31,32,33] and with loss-of-function mutations in Tumour Protein p53 (TP53) [34].